INTRODUCTION {#SEC1}
============

Ribosomes are highly conserved ribonucleoprotein complexes that are required for protein synthesis ([@B1]). In eukaryotes, the ribosomes are composed of two subunits, the 60S and 40S. The 60S subunit contains three rRNAs (28/25S, 5.8S and 5S) and ∼49 proteins while the 40S subunit contains a single rRNA (18S) and ∼33 proteins ([@B2]). Ribosome assembly is a major undertaking that occurs in the nucleus and requires coordinated expression of the different RNA and protein components ([@B3],[@B4]). The biogenesis of ribosomes involves hundreds of rDNA repeats and ribosomal protein genes (RPGs) and also requires ∼76 small nucleolar RNAs (snoRNAs) and \> 200 different assembly factors ([@B5]). This complex process has to meet the high demand for protein synthesis, without compromising quality or wasting energy. Accordingly, perturbing the expression of one or more components of the ribosome often impacts the ensemble of genes required for ribosome biogenesis and leads to defects at different levels of the assembly pipeline ([@B6]).

In the yeast *Saccharomyces cerevisiae*, the majority of ribosomal proteins (RPs) are produced from duplicated genes or ohnologs created by whole genome duplication ([@B7]). These ohnologs are believed to be functional paralogs preserved during evolution ([@B8],[@B9]), but the reason for their preservation is not entirely clear. There is still ongoing debate about whether duplicated RPGs (dRPGs) are preserved to ensure constant dose ([@B10],[@B11]) or to increase the functional diversity of RPs ([@B8],[@B12]). Most experimental deletions of duplicated genes generated copy-specific phenotypic effects, arguing against redundant functions. For example, the deletion of *RPL7A, RPL12B, RPL22A* and *RPS18B* and not their paralog affected the localized translation of Ash1 mRNA ([@B8]). Indeed, we have recently shown that the deletion of the minor and not the major copy of several dRPGs may affect growth under stress without major effect on the global amount of RP ([@B12],[@B13]). Deletions of duplicated genes were also shown to generate different transcription profiles and affect growth in a copy-specific manner, suggesting the dRPGs may serve different functions ([@B8]). Consistently, most paralogs are expressed at different levels and have different localization and assembly patterns suggesting that the expression of RPGs is functionally regulated in a copy-specific manner ([@B8]).

Systematic deletions of introns from dRPGs indicated that they might play an important role in defining the expression pattern of dRPGs ([@B12]). The majority of intron deletions affected the expression of the dRPGs in a paralog-specific manner. The presence of introns did not always lead to inhibition of gene expression, as would be expected from the obligate delay in gene expression caused by splicing. Instead, introns induced the expression of about half of the genes and inhibited the expression of the other half indicating that introns may function as modular gene-specific regulators of gene expression ([@B12]). Deletion of RPGs introns affected not only the expression of the host gene (intragenic regulation) but also altered the expression of its paralog *in trans* (intergenic regulation). This interplay between two splicing events in dRPGs provides a means to alter the specific ratio of similar but non-identical mRNAs, thus allowing modification of the constitution of ribosomes in certain growth conditions. Indeed, exposing cells to stress altered the expression ratio of the dRPGs in an intron-dependent manner and intron deletions altered sensitivity to drugs ([@B12]). For example, while exposing cells to caffeine favors the expression of the B form of the small subunit protein *RPS9*, exposure to NaCl favors the expression of the A form. Deleting the intron of *RPS9A* blocked the caffeine-dependent modulation of the paralog ratio by constitutively increasing the expression of *RPS9A* and preventing the induction of *RPS9B*. Similarly, exposing cells to staurosporine favored the expression of *RPS9A* and the deletion of its intron rendered the cell sensitive to staurosporine ([@B12]). Therefore, while deletion of the RPG introns demonstrated their importance as regulators of RP synthesis, the mechanism by which introns regulate the expression of duplicated genes and their impact on ribosome production remains unclear.

In this study, we examined the mechanism by which introns regulate the expression of dRPGs and evaluated their impact on the synthesis of RPs. Mutational analysis of the genes coding for the S9 protein indicated that the expression levels of these dRPGs, which produce two protein isoforms that differ by five amino acids ([@B14]), are defined by their different intron structures and the different nature of their 3′ end. The minor paralog (least expressed copy, *RPS9A*) has a long 3′ UTR and has an intronic two-way helical structure that inhibits splicing. Replacing these elements with the corresponding sequences of the predominant paralog (most expressed copy, *RPS9B*) enhanced splicing and increased the expression of *RPS9A*. Surprisingly, increasing the levels of the S9 proteins preferentially inhibited the splicing of the minor paralog. This suggests that the dose of dRPGs is regulated by an asymmetric negative feedback loop that maintains the correct level of expression of duplicated genes. Indeed, we show here that Rps9B differentially binds to the intron of *RPS9A* in the presence of the intronic element that is required for inhibiting the expression of *RPS9A*. Together our data provide an explanation for the preservation of introns in RPGs and they highlight the importance of splicing for controlling gene expression in yeast.

MATERIALS AND METHODS {#SEC2}
=====================

Strains and plasmids {#SEC2-1}
--------------------

Yeast strains were grown and manipulated using standard procedures ([@B15]). Strains carrying chromosomal copies of the 6 His-tagged version of *RPS9* were grown at 30°C in YEP media supplemented with 2% dextrose. Strains carrying plasmids expressing different versions of *RPS9* were grown at 30°C in synthetic media without leucine ([@B16]). Tagging the chromosomal copies of *RPS9* genes was achieved using a standard PCR based pop-in / pop-out method ([@B17]). *RPS9A* or *RPS9B* genes were replaced by the nutritional marker gene *URA3* ([@B18]) and the resulting knockout strains (*rps9aΔ::URA3* or *rps9bΔ::URA3)* were transformed by PCR fragments containing the tagged versions of *RPS9* genes ([@B19]). The primers used for the two-step PCR reactions are listed in Supplementary Table S1. Cells in which *URA3* was replaced by the tagged constructs were selected in media containing 5-FOA and the integration of the marker was verified using PCR. The tagged genes were introduced in the intron deletion strains described in Figure [1](#F1){ref-type="fig"} by mating and sporulation of the diploid strains ([@B17]). Mutations of the *RPS9* genes were generated by gene synthesis (Bio Basic Canada, Markham, ON), while the majority of sequence substitutions were achieved by standard cloning techniques using silent restriction sites introduced by gene synthesis (Bio Basic Canada, Markham, ON). The detailed description and sources of the different plasmids and strains used in this study are listed in Supplementary Tables S2 and S3, respectively. Plasmids were named using the standard nomenclature scheme where P indicated plasmids, H indicates Histidine tag, and each region of the gene (promoter, 5′ UTR, ORF and 3′ UTR) is indicated by letter A for *RPS9A* and letter B for *RPS9B*. US indicates the upper stem structure in the intron of *RPS9A* and M indicates mutations.

![Synthesis of the ribosomal protein S9 is regulated by asymmetric splicing of duplicated genes. (**A**) Schematic representation of the *RPS9* paralogs. The sizes of the 5′ untranslated region (5′ UTR), first exon (E1), intron, second exon (E2) and 3′ untranslated region (3′ UTR) are shown above each gene. The position of the 6-histidine tag (His6) used for the detection of *RPS9* mRNA and Rps9 proteins is indicated on the left. The percent homology between the different regions of the *RPS9* paralogs is shown below. (**B**) The expression of *RPS9A* is repressed under normal growth conditions. The RNA and proteins were extracted from cells expressing either a tagged version of either *RPS9A* (H-S9A) or *RPS9B* (H-S9B) and visualized using Northern blot (upper panel) and western blot (lower panel), respectively. The RNA was hybridized to probes complementary to the His6-tag sequence, while the protein was detected using antibodies against the tag. The position of *RPS9* mRNA and proteins is shown on the right. *ACT1* mRNA was used as loading control for the Northern blot and Pgk1 was used as loading control for the western blot. The relative mRNA expression (RME) and protein amounts (RPA) were calculated from three independent experiments and are indicated at the bottom along with the standard deviation (Std) for each data point. (**C**) The expression of *RPS9A* is repressed post-transcriptionally. Northern blots and Western blots were performed using the His6-tag as described in B to compare the expression of *RPS9A* mRNA and protein before and after the substitution of the *RPS9A* promoter and 5′ UTR with that of *RPS9B* (pH-B-AAA-A). (**D**) Introns asymmetrically regulate the expression of Rps9 mRNA. RNA was extracted from strains expressing normal or mutated versions of tagged *RPS9A* (S9A) or *RPS9B* (S9B) and the expression of the tagged RNA was detected using quantitative RT-PCR. H-S9 indicates mRNA extracted from strains carrying a tagged chromosomal copy of either *RPS9A* or *RPS9B*. Strains carrying intron deletions are indicated by Δi and those with complete gene deletions are indicated by Δ. The data are the average of three independent experiments. The asterisks indicate statistically significant differences between the mRNA levels detected in the mutated and non-mutated strains (\*\**P*-value \< 0.01 and \*\*\**P* \< 0.001). (**E**) Introns preferentially repress the production of Rps9A proteins. Proteins were extracted from the strains indicated in D and subjected to Western blot analysis using antibodies against the His6-tag as described in (B). (**F**) Expression of *RPS9B* inhibits the splicing of *RPS9A*. The splicing efficiency of *RPS9A* and *RPS9B* was evaluated by comparing the relative amount of the spliced (S) and unspliced (US) mRNA using end-point RT-PCR. The bands were detected using capillary electrophoresis and the relative migration of the PCR amplicon were simulated in the forms of bands. The size marker is shown on the left. The splicing levels of the tagged version of each RPG are listed in Supplementary Table S4. (**G**) *RPS9A* is spliced less efficiently than *RPS9B* pre-mRNA. Cells expressing a previously established yellow fluorescent protein (YFP) dependent synthetic splicing reporter carrying either the *RPS9A* or *RPS9B* intron were grown in synthetic media and the relative fluorescent units are presented in the bar graph. An intronless reporter (none) was used as a positive control and a reporter carrying a mutated or splice defective intron (mutated) was used as negative control. The data is an average of three independent experiments and the standard deviation is indicated as error bars.](gkw140fig1){#F1}

RNA extraction and analysis {#SEC2-2}
---------------------------

Total RNA was extracted from exponentially growing cultures using glass beads (425--600 μm, Sigma-Aldrich, St. Louis, MO) and Northern blot analysis was performed as previously described ([@B20]). Briefly, 15 μg of total RNA was separated on a 1.2% denaturing agarose gel and transferred to nylon membrane (Hybond N+, GE Healthcare, Mississauga, ON). The RNA was visualized by autoradiography using a labelled oligonucleotide complementary to the six His-tag or labeled probes corresponding to *ACT1* mRNA as control. Images were obtained using a phosphorimager (Storm 860, GE Healthcare, Mississauga, ON). The primers used to generate the probes are listed in Supplementary Table S1.

PCR and splicing index analysis {#SEC2-3}
-------------------------------

Total RNA was extracted, treated with DNase (Qiagen, Toronto, ON) and quantitative RT-PCR was performed as previously described ([@B12]). End-point PCR (30 cycles) was performed using Platinum Taq (Invitrogen Life Technologies, Burlington, ON) and 10 ng of cDNA as previously described ([@B21]). The sequences of the primers used for the PCR amplifications are shown in Supplementary Table S1.

Protein extraction and analysis {#SEC2-4}
-------------------------------

Proteins were extracted from exponentially growing cells using glass beads (425--600 μm; Sigma-Aldrich, St. Louis, MO) in lysis buffer (Tris 20 mM pH 8; NaCl 150 mM; Triton X-100 0.1%, PMSF 1 mM; Roche Protease inhibitor Cocktail tablets 1×, Roche Canada, Mississauga, ON). Cells were broken using five cycles of 30 s at 5000 rpm in a Precellys^®^ homogenizer (Laboratory Supply Network, Atkinson, NH) and 40 μg of total proteins were separated on 15% SDS-polyacrylamide gel and transferred to nitrocellulose membrane (Hybond-ECL; GE Healthcare, Mississauga, ON). Membranes were incubated in a hybridization solution (TBS-Tween 0.1%; milk 5%) with antibodies against the six His-tag (dilution 1:500; Santa Cruz Biotechnology, Santa Cruz, CA) or against Pgk1p, as loading control (dilution 1:10 000; Invitrogen Life Technologies, Burlington, ON). The proteins were visualized by chemiluminescence (Lightning Plus-ECL Chemiluminescence kit, Perkin Elmer, Woodbridge, ON) using secondary anti-mouse antibodies conjugated to horseradish peroxidase (dilution 1:2000; GE Healthcare, Mississauga, ON). The protein images were captured using LAS 4000 (GE Healthcare, Mississauga, ON) and the relative protein amounts were calculated using Quantity One software (Bio-Rad, Saint-Laurent, QC).

Growth and fluorescence measurements {#SEC2-5}
------------------------------------

Cells expressing yellow fluorescent protein (YFP) ([@B22]) were grown in synthetic media to a final concentration of 2 × 10^6^ cells/ml and 100 μl of the cell suspension of the different strains examined was transferred to a 96-well microplate to monitor either growth or fluorescence using the PowerWave XS and FLx800 microplate readers, respectively (BioTek Instruments, Winooski, VT). The relative fluorescence units (RFU) were calculated after ∼2.5 generations by subtracting the fluorescence units (FU) generated by a strain that does not express YFP from that generated by strains carrying different versions of the reporter gene.

Chromatin immunoprecipitation (ChIP) assays {#SEC2-6}
-------------------------------------------

Chromatin immunoprecipitation (ChIP) assays were performed as previously described ([@B23]). Briefly, cells were grown to an OD~600~ of 0.5--0.6. Formaldehyde solution was added into the culture to 1% final concentration and incubated for 20 min at room temperature. The fixation was quenched with glycine (0.36 M final) for 5 min. The cells were washed twice with cold Tris-buffered saline (20 mM Tris--HCl pH 7.5, 150 mM NaCl) and pellets were resuspended in FA lysis buffer (50 mM HEPES--KOH pH 7.5, 150mM NaCl, 1 mM EDTA pH 8, 1% Triton X-100, 0.1% sodium deoxycholate, protease inhibitors). Cells were disrupted using six cycles of 10 s at 6500 rpm in a Precellys^®^ homogenizer (Laboratory Supply Network, Atkinson, NH) and chromatin was sheared by 12 pulses of 10 s at 20% using Branson digital sonifier (Branson Ultrasonics, Danbury, CT). Whole-cell extracts were treated with 7.5 U RNase A (Affymetrix, Santa Clara, CA) and 300U RNase T1 (Sigma Aldrich, St. Louis, MO) for 30 min at 15°C. Untreated samples were also incubated under the same condition in the absence of ribonucleases as control. Immunoprecipitation was performed by incubating the different samples with HA antibody (1.5 μg; 12CA5; Sigma-Aldrich, St. Louis, MO) coupled to magnetic beads (Dynabeads Pan Mouse IgG, Invitrogen Life Technologies, Burlington, ON). The beads were washed and the eluates were collected. The eluates were decrosslinked by incubation in TE--SDS 1% buffer overnight at 65°C. The DNA was purified and detected using quantitative PCR as described ([@B23]). The sequences of the primers used for the PCR amplifications are shown in Supplementary Table S1.

RESULTS {#SEC3}
=======

Synthesis of Rps9 protein isoforms is regulated by asymmetric paralog specific splicing {#SEC3-1}
---------------------------------------------------------------------------------------

The fact that intron deletions differentially affect the expression of dRPGs suggests that differences in intron sequence may play an important role in controlling and coordinating the expression of RPGs ([@B12]). However, the intronic effects on RP synthesis and the mechanism by which they affect the expression of dRPGs remain unclear. To evaluate the effects of introns and other regulatory sequences on protein production, we generated tagged versions of a model dRPGs pair. *RPS9A* and *RPS9B* were chosen as the model for this study (Figure [1A](#F1){ref-type="fig"}) because introns of *RPS9* were retained during evolution ([@B24]) and their deletions altered growth under stress ([@B12]). The tagged copies of *RPS9* were created by inserting a six His-tag after the start codon of *RPS9A* (H-S9A) or *RPS9B* (H-S9B) to produce strains expressing one tagged paralog at a time. The tag inclusion did not affect growth and had no significant effect on RNA expression levels (Supplementary Table S4). By using one epitope in two different strains, we were able to directly compare the expression levels of *RPS9* paralogs using a single probe or antibody. As shown in Figure [1B](#F1){ref-type="fig"}, *RPS9B* produced 20 times more RNA and almost 60 times more proteins than *RPS9A*, indicating that *RPS9B* is the most expressed copy, or the 'housekeeping' gene, that produces the majority of S9 protein.

To understand the source of the great difference in the amount of proteins produced by the *RPS9* genes, we evaluated the effects of the intron and promoter sequence on gene expression. Promoters are considered important regulators of RPGs expression ([@B25],[@B26]) and thus were included in the assay as control. Surprisingly, the substitutions of the promoter and 5′ UTR of *RPS9A* with those of *RPS9B* in Figure [1C](#F1){ref-type="fig"} (pH-B-AAA-A; our convention of naming constructs states the origin of each part of the gene according to the system pHis- 5′ UTR - first exon / intron / second exon -- 3′ UTR) did not substantially increase the levels of *RPS9A* mRNA, indicating that the promoter identity is not responsible for the difference in the RNA levels of these two paralogs (Figure [1C](#F1){ref-type="fig"}, upper panel). This is also consistent with the *RPS9A* and *RPS9B* RNAPII and nucleosome association profiles, which indicate that *RPS9B* is not more transcribed than *RPS9A* (Supplementary Figure S1).

Despite the small difference in mRNA quantities detected upon the promoter substitutions, the presence of the *RPS9B* promoter and 5′ UTR increased Rps9A protein production by 3.7 times (Figure [1C](#F1){ref-type="fig"}, lower panel). This suggests that the sequence upstream of the coding sequence of *RPS9* may influence the translation of its paralog\'s mRNAs. In contrast, intron deletion substantially increased both the RNA and protein levels of *RPS9A* but not of *RPS9B* (Figure [1D](#F1){ref-type="fig"} and [E](#F1){ref-type="fig"}). This clearly indicates that the intron is the main cause of the preferential repression of *RPS9A*. Unexpectedly, while deletion of the *RPS9B* gene increased the expression of *RPS9A*, deletion of the *RPS9B* intron inhibited the expression of *RPS9A* (Figure [1D](#F1){ref-type="fig"} and [E](#F1){ref-type="fig"}). This suggests that whereas the presence of *RPS9B* represses the expression of *RPS9A*, its intron alleviates the repression of *RPS9A*, perhaps by competing for potential inhibitors *in trans*. We conclude that *RPS9B* is preferentially expressed over *RPS9A* due to asymmetric regulation by their respective introns.

To determine the mechanism by which introns influence the expression of *RPS9* paralogs, we compared the splicing efficiency of *RPS9A* and *RPS9B* pre-mRNAs and evaluated the effects of their introns on the splicing of a reporter gene. The amount of spliced and unspliced transcripts was detected by end-point RT-PCR using primers complementary to the region surrounding the splice site of each paralog. As indicated in Figure [1F](#F1){ref-type="fig"}, *RPS9A* generated a detectable quantity of unspliced RNA, while *RPS9B* did not. Deleting the 5′-3′ exoribonucleases that normally degrade unspliced pre-mRNA increased the amount of the paralog pre-mRNA and made it possible to detect the precursor of *RPS9B* (Supplementary Figure S2). However, even in the absence of ribonuclease we still detected more pre-mRNA for *RPS9A* than *RPS9B* (Supplementary Figure S2), consistent with the diminished splicing efficiency of *RPS9A*. To directly compare the splicing efficiency of the *RPS9* introns, we monitored their effect on the maturation of same reporter gene ([@B22]). As indicated in Figure [1G](#F1){ref-type="fig"}, the splicing reporter produced much more yellow fluorescent protein (YFP) with the intron of *RPS9B* than with that of *RPS9A*. This result confirms that the difference between the splicing efficiency of *RPS9A* and *RPS9B* is mostly determined by the intron sequence.

Deletion of the complete *RPS9B* gene enhanced the splicing (Figure [1F](#F1){ref-type="fig"}) and increased the expression of *RPS9A* (Figure [1D](#F1){ref-type="fig"} and [E](#F1){ref-type="fig"}). However, the deletion of the *RPS9B* intron, which does not increase the amount of S9B proteins (Figure [1E](#F1){ref-type="fig"}), resulted in strong inhibition of *RPS9A* splicing (Figure [1D](#F1){ref-type="fig"} and [F](#F1){ref-type="fig"}) and expression (Figure [1D](#F1){ref-type="fig"} and [E](#F1){ref-type="fig"}). This suggests that the introns of these two gene copies may communicate independently of the amount of proteins produced from their coding regions. Deletion of *RPS9A* (H-S9B;S9AΔ) and its intron (H-S9B;S9AΔi) had minor effect on protein levels and no effect on the splicing of *RPS9B* (Figure [1E](#F1){ref-type="fig"}--[F](#F1){ref-type="fig"}). We conclude that the introns of *RPS9* paralogs encode different splicing programs that define the expression level of their host genes.

Splicing efficiency is controlled by paralog specific intronic structure {#SEC3-2}
------------------------------------------------------------------------

Comparison of the splicing efficiency of *RPS9* paralogs indicated that *RPS9A* is less efficiently spliced than *RPS9B* (Figure [1F](#F1){ref-type="fig"} and [G](#F1){ref-type="fig"}). However, the reason behind this difference in the paralogs splicing efficiency is unclear. It was previously shown that intronic secondary structure might regulate splicing in yeast ([@B27]--[@B29]). Therefore, we compared the secondary structure of the *RPS9A* and *RPS9B* introns with the goal of identifying possible paralog-specific structural elements that might explain the difference in splicing efficiency. The intronic sequence of both *RPS9A* and *RPS9B* were folded using the nucleic acid folding and hybridization prediction program mfold ([@B30]) and consensus structures of each paralog found in other *Saccharomyces* species were retained and compared. As indicated in Figure [2A](#F2){ref-type="fig"}, both introns formed extended long range secondary structures that bring the 5′ and 3′ ends into close proximity, which seems to be a general feature of yeast pre-mRNA ([@B31]). Differences in the structure of the paralogs' introns were found in two regions, the first near the paired termini defining the splice sites and the second near the upper stem (US) loop structure (Figure [2A](#F2){ref-type="fig"}). To verify whether these variations in structures are indeed the reason for the differences in the splicing efficiency of *RPS9A* and *RPS9B*, we substituted the intron of *RPS9A* with that of *RPS9B* and monitored the effect on the splicing and expression of *RPS9A* mRNA. As indicated in Figure [2B](#F2){ref-type="fig"}, intron substitution (pH-A-ABA-A) significantly increased the amount of the mature mRNA generated by *RPS9A*, which confirms that differences in intron structure may influence paralog expression levels. The increase in the expression of pH-A-ABA-A raised the amount of the Rps9A protein without greatly affecting the expression of *RPS9B* (Figure [2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}). Remarkably, intron substitution did not change the ratio of *RPS9A* spliced and unspliced mRNA (Figure [1B](#F1){ref-type="fig"}). Therefore, while differences between *RPS9A* and *RPS9B* introns are sufficient to induce the expression of *RPS9A*, additional elements may influence the preferential stability of *RPS9A* pre-mRNA.

![The differential splicing of *RPS9* pre-mRNAs is generated by paralog specific intronic elements. (**A**) The introns of *RPS9A* and *RPS9B* have distinct structural elements. The secondary structures of the *RPS9A* and *RPS9B* introns were folded using mfold and the most likely conserved structures found in related *Saccharomyces* species are shown. (**B**) The intron sequence defines the splicing efficiency of the *RPS9* paralogs. The relative mRNA expression of tagged *RPS9A* (pH-A-AAA-A), *RPS9A* carrying the intron of *RPS9B* (pH-A-ABA-A) and *RPS9A* lacking the upper stem structure that differentiates introns between the *RPS9A* and *B* (pH-S9AUSΔA) were determined using quantitative RT-PCR. The splicing efficiency was determined as described in Figure [1F](#F1){ref-type="fig"} and presented in the form of a bar graph. The experiments were conducted in triplicates and statistically significant differences in expression and splicing efficiency are indicated by asterisks (\**P*-value \<0.05; \*\**P*-value \< 0.01 and \*\*\**P*-value \< 0.001). (**C**) Modification of the*RPS9A* intron has little effect on the expression of *RPS9B* mRNA. The levels of *RPS9B* were detected using quantitative RT-PCR in the different *RPS9A* strains described in (B). (**D**) The intron sequence regulates the expression of S9 proteins. The mutations described in B were expressed with (pH-A-AAA-A, pH-A-ABA-A and pH-S9AUSΔA) or without (p-A-AAA-A, p-A-ABA-A and p-S9AUSΔA) the His~6~-tag in strains lacking *RPS9A* (*s9aΔ*) or cells lacking *RPS9A* and expressing His-tagged *RPS9B* (*s9aΔ*; H-S9B) and the protein was extracted and visualized using antibodies against the His~6~-tag. The position of the S9 protein and loading control Pgk1 is shown on the right. The relative protein amount calculated from three independent experiments and their respective standard deviations are shown at bottom.](gkw140fig2){#F2}

To better characterize the intronic elements inhibiting the expression of *RPS9A*, we deleted the US structure (Figure [2A](#F2){ref-type="fig"}), which harbors most of the differences between the *RPS9* paralogs, and examined its effect on expression, splicing and protein synthesis. As predicted, the deletion of the *RPS9A* US (pH-S9AUSΔA) resulted in a significant increase in the *RPS9A* mRNA and reduced the amount of unspliced pre-mRNA (Figure [2B](#F2){ref-type="fig"}). This increase in mRNA induced the expression of Rps9A protein and inhibited the expression of Rps9B protein without significantly decreasing the levels of *RPS9B* mRNA (Figure [2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}). These data indicate that the ratio of the *RPS9* paralogs is defined by intronic structural elements that preferentially attenuate the splicing and inhibit the production of the *RPS9A* mRNA. Indeed, replacing the US loop structure of A with that of B is sufficient to enhance the splicing and increase the expression of *RPS9A* (Supplementary Figure S3). To identify the specific structural element that regulates the splicing of *RPS9* paralogs, we divided the US loop structure of *RPS9A* into three regions and examined the effect of each mutated region on expression and splicing efficiency (Figure [3A](#F3){ref-type="fig"}). As indicated in Figure [3B](#F3){ref-type="fig"}, mutations of regions I and II (S9A-MI and S9A-MII), which are located on each side of the lower region of the US structure, did not increase the levels of mature *RPS9A* mRNA or enhance splicing. S9A-MII did not affect protein production, while S9A-MI resulted only in a moderate increase in protein production (Figure [3D](#F3){ref-type="fig"}). In contrast, mutations in region III (S9A-MIII), which includes the putative two-way helical structure, enhanced splicing and increased expression of *RPS9A* significantly (Figure [3B](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}). Despite the substantial increase in S9A-MIII proteins, the amount of *RPS9B* mRNA did not change (Figure [3C](#F3){ref-type="fig"}). In any case, the data clearly indicate that while different mutations may influence gene expression only mutations disrupting the two-way helical structure (S9A-MIII) enhance splicing. We conclude that the splicing of *RPS9A* is inhibited by a putative two-way helical structure that differs in junction size and stem orientation between paralogs.

![Splicing of *RPS9A* is inhibited by a putative two-way helical structure. (**A**) Schematic representation of the *RPS9A* upper stem structure (S9A-US) required for the inhibition of *RPS9A* splicing and its mutated derivatives. The roman numbers indicate the three subsections of S9A-US targeted for mutation. The mutated regions are highlighted and identified by roman number (I--III). (**B**) Disruption of the upper stem two-way junction promotes the splicing and increases the expression of *RPS9A*. The relative mRNA expression and splicing efficiency were determined using PCR and presented in the form of a bar graph. The experiments were conducted in triplicates and statistically significant differences are indicated by asterisks (\*\**P*-value \< 0.01 and \*\*\**P*-value \< 0.001). (**C**) Disruption of *RPS9A* upper stem structure has limited effect on the expression of *RPS9B*. The expression of *RPS9B* in the different *RPS9A* mutations was determined by quantitative RT-PCR and presented in the form of bar graph. (**D**) Disruption of the putative two-way helical structure induced the expression of the Rps9A protein. The relative protein amounts (RPA) and standard deviations were calculated using three independent experiments and shown at bottom.](gkw140fig3){#F3}

Splicing of *RPS9B* is promoted by multiple elements ensuring efficient splicing and translation {#SEC3-3}
------------------------------------------------------------------------------------------------

To determine whether the intron of *RPS9A* is sufficient for inhibiting the expression of its host gene and to understand how the expression of *RPS9B* is regulated, we substituted the non-coding sequences of *RPS9B* with those of *RPS9A* and determined the impact on expression (Figure [4A](#F4){ref-type="fig"}). As indicated in Figure [4B](#F4){ref-type="fig"}, the intron substitution (pH-B-BAB-B) greatly inhibited the expression of *RPS9B*, confirming the capacity of *RPS9A* intron to independently inhibit gene expression. The substitution of both the *RPS9B* promoter and intron sequences with those of *RPS9A* (pH-A-BAB-B) did not decrease the expression level of *RPS9B* (Figure [4B](#F4){ref-type="fig"}). This suggests that *RPS9A* is normally more transcribed than *RPS9B*. Indeed, ChIP-Seq data indicate that RNAPII associates more with *RPS9A* than with *RPS9B* and more nucleosomes are found near the promoter of *RPS9B* than that of *RPS9A* (Supplementary Figure S1). Therefore, while *RPS9A* might be more transcribed than *RPS9B*, the relative amount of the mature mRNA available for translation is influenced by differences in the splicing efficiency of these two duplicated genes.

![Expression of *RPS9B* is promoted by both intron and 3′ UTR sequences. (**A**) Schematic representation of the *RPS9* genes and its associated *RPS9B* mutations. The size of the promoter (P), exons (E), introns (I) and 3′ UTR is indicated above each gene in nucleotides (nt). The name of each mutant is indicated on the right. The sequence of *RPS9A* is outlined in black while that of *RPS9B* outlined in gray. (**B**) The intron and 3′ UTR of *RPS9A* inhibit the expression of *RPS9B*. The expression of the different mutations of *RPS9B* indicated in A was detected using quantitative RT-PCR and shown in the form of a bar graph. The experiments were conducted in triplicates and statistically significant differences in expression are indicated by asterisks (\*\* *P*-value \< 0.01 and \*\*\**P*-value \< 0.001). (**C**) Inclusion of the *RPS9A* intron and 3′ UTR in *RPS9B* has little effect on the expression of *RPS9A*. The splicing of *RPS9A* and the level of mature mRNA were detected using RT-PCR and indicated in the form of a bar graph. (**D**) Changes in the levels of *RPS9B* mRNA have limited effect on the expression of Rps9B protein. The effect of the different mutations on protein levels was monitored using a His6-tag specific antibody. The expected position of the S9 and the control protein Pgk1 is shown on the right. The relative protein amounts and the standard deviation were determined using three independent experiments and indicated at the bottom.](gkw140fig4){#F4}

The substitution of the 3′ UTR of *RPS9B* with that of *RPS9A* (pH-B-BBB-A) reduced the expression of *RPS9B* but not to the same level as the intron substitution (pH-B-BAB-B) (Figure [4B](#F4){ref-type="fig"}). Substitution of all non-coding sequences of *RPS9B* with those of *RPS9A* within the same construct did not further reduce the expression of *RPS9B* (pH-A-BAB-A) (Figure [4B](#F4){ref-type="fig"}). Additionally, the unspliced mRNA was not detected for any of the constructs containing the coding sequence of *RPS9B* under normal growth condition (Supplementary Table S4). However, the mutant *RPS9B* containing the intron of *RPS9A* (pH-B-BAB-B) had increased accumulation of pre-mRNA in the absence of the ribonucleases that normally degrade unspliced pre-mRNA (Supplementary Figure S2). Therefore, while the intron and the 3′ UTR may alter the levels of *RPS9B* mRNA (pH-B-BAB-B and pH-B-BBB-A), other sequences embedded within the coding sequence contribute to the instability of *RPS9B* pre-mRNA (Supplementary Figure S2). The introduction of *RPS9A* regulatory elements in *RPS9B* did not greatly affect the expression of *RPS9A* because none of the mutations greatly reduced the amount of Rps9B protein under the conditions tested (Figure [4C](#F4){ref-type="fig"} and [D](#F4){ref-type="fig"}). The amount of Rps9B proteins produced by the different substitutions (e.g. pH-A-BAB-B and pH-A-BAB-A) did not correlate directly with the amount of mRNA produced from each construct. This suggests that unlike *RPS9A*, the expression of *RPS9B* might also be regulated at the level of translation (Figure [4B](#F4){ref-type="fig"} and [D](#F4){ref-type="fig"}). Comparison of the paralog codon usage frequency indicated that *RPS9B* mRNA contains more codons with higher usage frequency than *RPS9A* (Supplementary Figure S4), which may promote the translation of the Rps9B isoform over its Rps9A counterpart. Overall these observations indicate that while differential repression of dRPGs is achieved by a simple modification of mRNA levels, the preferential expression of the dominant copy can be achieved by multiple factors at several levels of gene expression.

The 3′ UTR of *RPS9* influences splicing in an intron dependent manner {#SEC3-4}
----------------------------------------------------------------------

The capacity of *RPS9A* 3′ UTR to reduce the expression of *RPS9B* (Figure [4B](#F4){ref-type="fig"}) suggests that elements other than the intron might also modulate the expression of *RPS9A*. To verify this possibility, we substituted the promoter and 3′ end of the *RPS9A* with those of *RPS9B* and monitored the effect on expression (Figure [5A](#F5){ref-type="fig"}). Surprisingly, the substitution of *RPS9A* 3′ UTR with that of *RPS9B* (pH-A-AAA-B) not only resulted in a significant increase in the expression of *RPS9A*, but also reduced the proportion of unspliced mRNA (Figure [5B](#F5){ref-type="fig"}). Substitution of both the 3′ end and the intron of *RPS9A* (e.g. pH-A-ABA-B) reduced the amount of unspliced mRNA and further increased the expression of *RPS9A* mRNA to levels comparable to those observed with the intact *RPS9B* (Figure [5B](#F5){ref-type="fig"}). Substitution with the *RPS9B* promoter (pH-B-ABA-B) did not increase the expression any further suggesting that both the intron and the 3′ UTR collaborate to inhibit the expression of *RPS9A* regardless of the promoter used for transcription. The substitution of the intron and 3′ UTR of *RPS9A* (pH-A-ABA-B) also inhibited the expression and reduced the splicing of *RPS9B in trans* (Figure [5C](#F5){ref-type="fig"}). This decrease in the expression of *RPS9B* is not necessarily due to increased production of Rps9A protein (Figure [5D](#F5){ref-type="fig"}) since other mutations that also increase the amount of Rps9A protein (e.g. pH-S9AMIII, Figure [3D](#F3){ref-type="fig"}) did not reduce the amount of *RPS9B* mRNA (Figure [3C](#F3){ref-type="fig"}). Instead, we propose that the introduction of extra copies of the *RPS9B* intron and 3′ end sequesters factors necessary for the expression of the chromosomal copy. As observed with mRNA (Figure [5B](#F5){ref-type="fig"}), the highest increase in the level of the Rps9A protein was observed with the substitution of both intron and 3′ UTR (pH-A-ABA-B, Figure [5D](#F5){ref-type="fig"}). However, a significant increase in protein expression was also observed with the substitution of the 3′ UTR alone (pH-A-AAA-B), which confirms that both the intron and the 3′ UTR can independently regulate protein production by altering the splicing efficiency. We conclude that the ratio of the dRPGs, at least in the case of *RPS9*, is determined mostly post-transcriptionally through differences in introns and the 3′ end sequences.

![*RPS9A* 3′ UTR mediates intron dependent attenuation of splicing. (**A**) Schematic representation of the *RPS9* genes and its associated *RPS9A* mutations. The size of the promoter (P), exons (E), introns (I) and 3′ UTR is indicated above each gene in nucleotides (nt). The name of each mutant is indicated on the right. The sequence of *RPS9A* is outlined in black with that of *RPS9B* in gray. (**B**) The 3′ UTR of *RPS9B* induces the splicing and increases the expression of *RPS9A*. The splicing and the expression of the different mutations of *RPS9A* indicated in A were detected using RT-PCR and are shown in the form of a bar graph. The experiments were conducted in triplicates and statistically significant differences are indicated by asterisks (\*\**P*-value \< 0.01 and \*\*\**P*-value \< 0.001). (**C**) Inclusion of both the *RPS9B* intron and its 3′ UTR in the *RPS9A* gene repress the expression of *RPS9B in trans*. The splicing of *RPS9B* and the level of mature mRNA were detected using RT-PCR and are indicated in the form of a bar graph. (**D**) The intron and 3′ end sequences collaborate to repress the expression of Rps9A protein. The effect of the different mutations on protein levels was monitored using antibodies specific to the His~6~-tag. The expected positions of the S9 and the control protein Pgk1p are shown on the right. The relative protein amounts and the standard deviation were determined using three independent experiments and indicated at the bottom.](gkw140fig5){#F5}

The S9 protein differentially interacts with the intronic sequence of the duplicated *RPS9* genes {#SEC3-5}
-------------------------------------------------------------------------------------------------

The two-way helical structure (US, Figure [2A](#F2){ref-type="fig"}) required for inhibiting the splicing of *RPS9A* features a central bulge similar to that required for the binding of the Rps9 protein to 18S rRNA ([@B32]). Therefore, we hypothesized that *Rps9B* may inhibit the expression of *RPS9A* by binding to the intron and inhibiting its splicing. However, testing the interaction between Rps9 protein and the introns of the *RPS9* genes is difficult since very little unspliced mRNA is detected for these two genes (Figure [1F](#F1){ref-type="fig"}). Alternatively, since most pre-mRNAs are believed to be spliced co-transcriptionally ([@B33],[@B34]), we reasoned that Rps9 protein might be present at the chromatin of the duplicated *RPS9* genes in an intron-dependent manner. To verify this possibility, we immunoprecipitated an HA-tagged version of the *RPS9* paralogs before and after RNase treatment. As indicated in Figure [6A](#F6){ref-type="fig"}, DNA fragments corresponding to the intron, the beginning of exon 2 and the 3′ UTR of *RPS9A* were enriched by the immunoprecipitation of Rps9B protein. In contrast, mock precipitation in the absence of antibodies and amplification using primers against unrelated RPGs did not enrich any of the DNA fragments. The biggest enrichment was detected in fragments within the intron and around the exon 2 splice site (fragments 2 and 3). Enrichment was also observed in fragments corresponding to the *RPS9B* intron and exon 2 (fragments 6 and 7) but to a lesser extent. Furthermore, unlike *RPS9A*, no significant enrichment was observed in the intron of *RPS9B* when compared with its 3′ UTR. All observed enrichments were lost after ribonuclease treatment as would be expected if the interaction between Rps9B protein and the chromatin of the duplicated genes is mediated by RNA. Together these data indicate that while Rps9B protein may interact with different parts of the duplicated transcripts it has higher affinity to the intron and exon 2 splice site of *RPS9A*. Mutation of the two-way helical structure that inhibits the splicing of *RPS9A* (Figure [3A](#F3){ref-type="fig"}) reduced the interaction of the intronic sequence with Rps9B to a similar level to that observed with the intron of *RPS9B* and this had little effect on the capacity of Rps9B to interact with the 3′ end sequence (Figure [6B](#F6){ref-type="fig"}). Therefore, while Rps9B may be recruited to chromatin by multiple sequences within the Rps9A and B mRNAs, its recruitment is enhanced in the presence of the *RPS9A*-specific helical structure. Together these data suggest that the differential inhibition of the *RPS9* paralogs is achieved through differences in the introns' affinity for Rps9 protein.

![Rps9B protein binds to the intron of *RPS9A* in the presence of the two-way helical structure required for inhibiting the splicing of *RPS9A* pre-mRNA. (**A**) Rps9B protein differentially interacts with the chromatin of the *RPS9* paralogs in an RNA dependent manner. ChIP assays were performed using an HA tagged version of Rps9B isoform before (dark gray bars) or after (light gray bars) RNase treatment and the co-precipitated DNA was detected using paralog specific primers. The enrichment of the different PCR amplicons relative to an untranscribed region in chromosome V is presented in the form of a bar graph. The position of the primers used is shown relative to the paralog gene\'s structures under the graph. The untranslated regions and introns are shown as lines and exons as boxes. The experiments were conducted in triplicates and the standard deviations are shown as error bars. DNA enrichments were considered significant when greater than 30% relative to the untranscribed control (dotted line). Statistically significant differences between RNase treated and untreated samples are indicated by asterisks (\**P*-value \<0.05, \*\**P*-value \< 0.01 and \*\*\**P*-value \< 0.001). (**B**) The Rps9B interaction with *RPS9A* is enhanced in the presence of the two-way helical structure required for the inhibition of *RPS9A* expression. The interaction of Rps9B with DNA originating from plasmids carrying wild type *RPS9A* (pH-A-AAA-A) or *RPS9A* with mutated two-way helical structure (pHS9A-MIII) was assayed before (--) or after (+) treatment with RNase using ChIP as described in (A). The position of the primers is shown below the graph. Significant differences between the enrichment patterns of the wild type gene and its mutated versions are indicated by asterisks (\*\**P*-value \< 0.01).](gkw140fig6){#F6}

Introns define the expression hierarchy of many dRPGs {#SEC3-6}
-----------------------------------------------------

To evaluate the generality of the *RPS9* mode of inter-paralog gene regulation, we compared the expression levels of the dRPGs to the splicing efficiency of their introns and determined the number of genes where low expression levels correlated with reduced splicing efficiency. The expression ratio of dRPG paralogs was calculated by comparing the expression levels of each gene as determined by single molecule sequencing ([@B35]), while the relative splicing efficiency of each gene pair was calculated by comparing the amount of spliced mRNA generated by a reporter gene carrying the introns of the different dRPGs ([@B22]). As indicated in Supplementary Table S5 and Supplementary Figure S5A, 71% (27 out of 38) of dRPGs tested were both under expressed and their intron less spliced when compared to their paralog. This indicates that, in most cases, splicing determines the paralog relative expression levels of the paralogs. Indeed, in 83% of the cases deleting the under-spliced intron from the minor dRPG copy led to increased expression of the host gene (Supplementary Table S5 and Supplementary Figure S5B). Strikingly, in 57% of the cases the deletion of the minor copy intron completely changed the paralog expression hierarchy also gave dominance to the otherwise minor copy. As in the case of *RPS9* (Figure [5](#F5){ref-type="fig"}), 12 out of these 15 genes with a strict intron-dependent expression hierarchy also have longer 3′ UTRs than their counterparts (Supplementary Table S5). This is consistent with a role of the UTR length in enforcing the splicing inhibition of the minor dRPG copies. We conclude that the expression hierarchy of several dRPGs is determined in large part post-transcriptionally by the intron identity assisted at least in some cases by other elements like the 3′ UTR length.

DISCUSSION {#SEC4}
==========

Previous studies indicated that introns influence the expression of dRPGs in a paralog specific manner ([@B12]). However, the mechanism by which introns regulate the expression of dRPGs and their impact on the accumulation of RPs remained unclear. In this study, we show that differences in intron structure determine the expression levels of dRPGs by influencing their splicing efficiency. The study of *RPS9*A and *RPS9B* indicated that the expression hierarchy of these duplicated genes is determined by copy specific intronic structures that differentially interact with the Rps9 protein. The presence of a putative two way helical structure in the intron of the minor copy (*RPS9A*) increased binding to the Rps9 protein and reduced splicing to favor the expression of the major copy (*RPS9B*) (Figures [3](#F3){ref-type="fig"} and [6](#F6){ref-type="fig"}). Mutational analysis indicated that while the repression of *RPS9A* was primarily based on the nature of intron and 3′ UTR the promotion of *RPS9B* expression requires additional elements embedded within the coding sequence (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). Together, the data indicate that the expression hierarchy of dRPGs is not simply achieved by accidental repression of the minor paralog during evolution, but rather represents a deep-rooted post-transcriptional regulatory program that promotes the expression of one copy over the other.

Most yeast introns are found in genes coding for RPs, which begs the question as to whether introns make a special contribution to the expression and function of RPGs ([@B36]). Previous studies using RNA as a marker for gene expression indicated that half of the RPGs are repressed in the presence of introns, while the other half is induced in their absence ([@B12]). In addition, studies of the large subunit protein gene *RPL30* and the small subunit protein gene *RPS14B* indicated that the intron structure play an important role in regulating the splicing efficiency and expression level of these genes ([@B28],[@B37]). However, the impact of these introns on the synthesis of RPs and the mechanism by which they regulate the expression of dRPGs remained unclear. In this study, we show that introns may directly affect the production of RPs by modifying the splicing of the dRPGs in a paralog specific manner. Comparison of the duplicated genes producing the small subunit protein Rps9 indicated that introns carry paralog-specific splicing structures that permit the inhibition of one copy and induce the expression of the other. This mode of differential regulation is not limited to *RPS9* but extend to other gene pairs (Supplementary Figure S5 and Supplementary Table S5). Indeed, a well-defined structure in the intron of *RPS14B*, and not *RPS14A*, was shown to inhibit the splicing of its host gene in response to changes in the levels of Rps14p ([@B37]). Accordingly, we propose that introns may function as codes for gene expression that help cells to program mini-circuits of inter-gene regulation. These codes would permit the coordination of the duplicated gene\'s expression without interfering with the general transcription program that control ribosome production.

Together, our data suggest a model (Figure [7](#F7){ref-type="fig"}) in which intron structure and 3′ UTR size determine the relative expression levels of dRPGs. This mode of asymmetric gene expression permits the adjustments of the paralogs expression levels without interfering with the promoter-dependent regulatory network at the root of ribosome synthesis control ([@B25]). In this model, the two RPG copies are not necessarily preserved to maintain constant dose of RPs but instead serve as tools to broaden the regulatory spectrum of RPGs. This notion is supported by the fact that the minor copy of the dRPGs does not fully compensate for the loss of its paralog (Supplementary Table S4) and increasing the amount of RP (e.g. expression of extra copies of *RPS9*, Supplementary Table S6) does not inhibit the expression of the paralog producing the majority of the RP (*RPS9B*). Instead, it is the minor copy (*RPS9A*) that is preferentially repressed by the Rps9 protein, perhaps through direct interaction between the Rps9 protein and the intron of *RPS9A* (Figure [6](#F6){ref-type="fig"}).

![Schematic representation of the multi level *RPS9* regulatory circuit. The differential regulation of *RPS9A* and *RPS9B* is illustrated at different levels of gene expression. The coding regions are shown in the form of boxes and non-coding sequence (introns and UTRs) are shown as lines. The transcription start sites are illustrated by arrows. The secondary structure within the *RPS9A* intron represents the structure required for the inhibition of *RPS9A* splicing. Steady state inhibition and enhancement of splicing are illustrated by gray lines.](gkw140fig7){#F7}

The ratio of the *RPS9* paralogs is maintained under normal growth conditions regardless of the amount of protein produced (Supplementary Table S4) but their relative expression is dramatically altered under stress ([@B12]). Exposure to osmotic stress reverses the ratio of *RPS9* paralogs by increasing the expression of *RPS9A* and repressing the expression of *RPS9B* ([@B12]). Deleting the introns perturbs the expression of both paralogs and results in a constitutive induction of *RPS9A* and conceals the response to stress. Therefore, it appears that the minor copy of the RPG pairs is preserved to adjust expression under different growth conditions and perhaps to produce alternative protein isoforms that are better suited for growth under stress. The *RPS9* protein isoforms vary by 5 amino acids, which slightly increases the charge of the C-terminal portion of the minor copy ([@B14]). Deleting the region harboring these alternative amino acids altered the ribosome association with many mRNAs ([@B14]). However, it remains to be seen if these amino acid differences are sufficient to explain the requirement of *RPS9A* for growth under stress. In all cases, the models presented in this study provide an explanation of the preservation of introns in RPGs and highlight the importance of splicing for gene regulation in yeast.
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